Follicular Lymphoma Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Follicular Lymphoma Treatment Market: By Treatment Type (Chemotherapy, Targeted Therapy, Radiotherapy, Monoclonal Antibodies, Stem Cell Transplantation), By Route of Administration (Oral, Parenteral), By End-User (Hospitals, Oncology Centers, Academic Research Institutes) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global Follicular Lymphoma Treatment Market size valued at USD 3.2 billion in 2021 and expected to reach USD 5.24 billion by 2028, at a CAGR of 7.3% during the forecast period 2022 to 2028. Follicular lymphoma treatment market is poised to grow at significant rate owing to increase in the R&D activities for the innovation newer therapies and drugs. Most of the international players are actively involved in the development of newer products. For instance, in December 2015, Novartis announced phase IIa study results of CTL019 used in the treatment of certain types of lymphoma including follicular lymphoma. Moreover, rising adoption of monoclonal antibodies for targeted therapies propels the follicular lymphoma treatment market. Furthermore, acquisitions and mergers, collaborations, product approvals, and product launchings are the strategies followed by the market players for gaining larger revenue share in follicular lymphoma treatment market. For instance, in February 2017, Health Canada approved Roche’s Gazyva (Obinutuzumab) for patients with previously treated follicular lymphoma. In addition, in August 2017, Epizyme, Inc. and US Oncology Research are collaborated to identify the non-Hodgkin lymphoma patients with EZH2 mutations and eligible patients are directed to ongoing phase 2 clinical trial of Tazemetostast in diffuse large B-cell lymphoma and follicular lymphoma. Follicular lymphoma is the second most common indolent non-Hodgkin’s lymphoma and it develops when the body makes abnormal B-lymphocytes in lymph nodes. The symptoms associated with follicular lymphoma include enlargement of lymph nodes in neck, abdomen, and groin, weight loss, difficulties in breathing, fatigue, and night sweats. Follicular lymphoma is diagnosed by biopsy, blood tests, and X-rays among others. Follicular lymphoma can be treated with chemotherapy, radiation therapy, targeted therapy, and stem cell transplant.

Follicular Lymphoma Treatment Market

MARKET SUMMARY
-
7.3% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 7.3%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Follicular Lymphoma Treatment Market

  • The report on global Follicular Lymphoma Treatment Market gives historical, current, and future market sizes (US$ Mn) on the basis of type of treatment type, route of administration, end user and geography.
  • Follicular Lymphoma Treatment Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa
Key Players
  • Hoffmann La Roche Ltd. (Switzerland)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • Merck & Co. Inc. (U.S.)
  • AbbVie, Inc. (U.S.)
Dynamics

Follicular Lymphoma Treatment Market

Rise in prevalence of follicular lymphoma, family history of blood disorders, increase in R&D activities for the innovation of newer drugs, and technological advancements in disease diagnosis are anticipated to fuel the follicular lymphoma treatment market. Moreover, promising pipeline products, innovation of newer therapies such as monoclonal antibodies, and government initiations for the cancer management are expected to boost the market over the forecast period. However, stringent regulatory policies for drug approval, the high cost of treatment, and adverse effects associated with the treatment are expected to hamper the growth of follicular lymphoma treatment market over the forecast years.


North-America got significant share

Follicular Lymphoma Treatment Market

Geographically, global follicular lymphoma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North Americafollicular lymphoma treatment market is poised to grow at notable rate due to increase in the prevalence of follicular lymphoma (according to American Cancer Society, approximately 20% of follicular lymphoma cases observed among all types lymphoma patients), increase in R&D activities for the innovation of newer drugs, an increase in healthcare expenditure in the region. Europefollicular lymphoma treatment market is expected to grow significantly due to the adoption of newer therapies, sophisticated healthcare infrastructure, an increase in the prevalence of follicular lymphoma due to change in lifestyle in the region. Asia Pacificfollicular lymphoma treatment market has a lucrative growth owing to the large patient pool, increase in awareness about lymphoma treatment, and government initiations for the prevention of cancer are expected to fuel the market in the region. Latin Americafollicular lymphoma treatment market expected to grow at moderate rate due to the expansion of business into the region by market players, adoption of newer drugs, and economic growth are bolster the market. Middle East and Africafollicular lymphoma treatment market have a growth attributed to rising in awareness about lymphoma treatment, increase in the prevalence of follicular lymphoma, and growing per capita income

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market and forecast
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Follicular Lymphoma Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Hoffmann La Roche Ltd. (Switzerland)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • Merck & Co. Inc. (U.S.)
  • AbbVie, Inc. (U.S.)
  • Bayer AG (Germany)
  • Epizyme Inc. (U.S.)
  • Bristol Myers Squibb (U.S.)
  • Johnson and Johnson Services Inc. (U.S.)

Description

The global Follicular Lymphoma Treatment Market size valued at USD 3.2 billion in 2021 and expected to reach USD 5.24 billion by 2028, at a CAGR of 7.3% during the forecast period 2022 to 2028. Follicular lymphoma treatment market is poised to grow at significant rate owing to increase in the R&D activities for the innovation newer therapies and drugs. Most of the international players are actively involved in the development of newer products. For instance, in December 2015, Novartis announced phase IIa study results of CTL019 used in the treatment of certain types of lymphoma including follicular lymphoma. Moreover, rising adoption of monoclonal antibodies for targeted therapies propels the follicular lymphoma treatment market. Furthermore, acquisitions and mergers, collaborations, product approvals, and product launchings are the strategies followed by the market players for gaining larger revenue share in follicular lymphoma treatment market. For instance, in February 2017, Health Canada approved Roche’s Gazyva (Obinutuzumab) for patients with previously treated follicular lymphoma. In addition, in August 2017, Epizyme, Inc. and US Oncology Research are collaborated to identify the non-Hodgkin lymphoma patients with EZH2 mutations and eligible patients are directed to ongoing phase 2 clinical trial of Tazemetostast in diffuse large B-cell lymphoma and follicular lymphoma. Follicular lymphoma is the second most common indolent non-Hodgkin’s lymphoma and it develops when the body makes abnormal B-lymphocytes in lymph nodes. The symptoms associated with follicular lymphoma include enlargement of lymph nodes in neck, abdomen, and groin, weight loss, difficulties in breathing, fatigue, and night sweats. Follicular lymphoma is diagnosed by biopsy, blood tests, and X-rays among others. Follicular lymphoma can be treated with chemotherapy, radiation therapy, targeted therapy, and stem cell transplant.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX